Drug intelligence / Profile preview

puyuanhewei

Development stage: Unknown
Lead developer: Qingdao Huaren Tery Pharmaceutical
Administration: Oral

Overview

Puyuanhewei is a Chinese patent medicine (CPM) primarily used for the treatment of gastrointestinal disorders, including functional dyspepsia and Helicobacter pylori-positive peptic ulcers. It is typically formulated as a capsule and manufactured by Zibo Buchang Pharmaceutical. The medication is designed to improve gastric mucosal barrier function and alleviate symptoms such as epigastric pain, bloating, and acid reflux. Clinical evidence suggests that when used in combination with standard triple or quadruple antibiotic therapies, Puyuanhewei can enhance H. pylori eradication rates and promote the healing of peptic ulcers.

Brand names: Puyuanhewei
Other names: Puyuanhewei capsulePuyuanhewei granule

Beyond the preview

Go deeper on puyuanhewei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on puyuanhewei.

Explore the full profile